PYXS Nasdaq Pharmaceutical Preparations Financials FY2020βFY2025
Pyxis Oncology, Inc. had $13.9M of revenue in fiscal 2025, down 14.2% on the year before.
Last close Β· Oct 23, 2026
$1.68
1.8%Hi! I read Pyxis Oncology, Inc.βs latest annual report (fiscal 2025). Here is what stands out:
Good So-so Weak
Are sales growing?
β14.2%
No. Sales fell 14.2% last year.
Does it make a profit?
β574.5%
No. It lost money last year.
Does profit turn into cash?
β458.3%
No. It spent more cash than it brought in.
How healthy are the accounts?
2 / 8
Weak. It passes 2 of 8 health tests.
How is the share priced?
β
No P/E: it made no profit over the last four quarters.
Rules of thumb on reported numbers. A starting point, not a recommendation.
Is it selling more, and how much does it keep?
KIRA Β· Pyxis Oncology, Inc. had $13.9M of revenue in fiscal 2025, down 14.2% on the year before. Its operating margin was β609.2%, down 55.1Β pts: of every 100 in sales, about β609 is left after running the business.
In plain words: Revenue is all the money customers paid. The margins show how many cents of each dollar of sales are left over at each step: after making the product (gross), after running the business (operating) and after everything, tax included (net).
Revenue
Revenue
Margins, % of revenue
Margins, % of revenue
KIRA Β· Pyxis Oncology, Inc. lost $79.6M in fiscal 2025.
Loss periods are shown in red.
In plain words: Net income is the profit left after every cost and tax. Earnings per share (EPS) splits that profit across every share, so it shows what one share earned.
Net income
Net income
Diluted EPS
Diluted EPS
How much cash comes in, and where does it go?
KIRA Β· Free cash flow was β$63.5M in fiscal 2025, β458.3% of revenue.
Cash from operations minus capital spending.
In plain words: Profit on paper is not the same as cash in the bank. Free cash flow is the cash left after paying to run and maintain the business: the money it can hand back to shareholders, save or invest.
Free cash flow
Free cash flow
Cash from operations vs capital spending
Cash from operations vs capital spending
In plain words: Companies hand cash back in two ways: dividends (cash paid to shareholders) and buybacks (buying back their own shares, so each remaining share owns a bigger slice).
Dividends and buybacks
Diluted shares outstanding (annual)
KIRA Β· In the last 12 months, insiders sold $0.1M of shares on the open market and bought none.
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. βPlanβ marks trades under a pre-arranged Rule 10b5-1 plan.
In plain words: Insiders are the people who run or own a big part of the company. Buying with their own money can signal confidence; selling often has personal reasons, like taxes or diversifying.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.1M
1 insider
Of sales under plans
100%
$0.1M
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Jun 30, 2026 | Jakob DupontDirector | Sold plan | 35,000 | $3.06 | $0.1M | Form 4 |
| Apr 21, 2025 | Rachel HumphreyDirector | Sold plan | 13,896 | $1.03 | $0.0M | Form 4 |
| Apr 17, 2025 | Rachel HumphreyDirector | Sold plan | 200 | $0.97 | $0.0M | Form 4 |
| Apr 14, 2025 | Rachel HumphreyDirector | Sold plan | 1,400 | $0.97 | $0.0M | Form 4 |
Can it carry its debts, and how well does it use its money?
Cash, debt and the ratios that show how comfortably Pyxis Oncology, Inc. can carry it.
In plain words: What the company owns and what it owes. More cash than debt is a cushion for bad times; a lot of debt leaves less room when business slows down.
Cash vs debt (incl. leases)
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | $275M | $179M | $119M | $127M | $66.9M |
| Current ratio | 14.9x | 5.9x | 4.8x | 7.5x | 3.4x |
| Quick ratio | 14.9x | 5.9x | 4.8x | 7.5x | 3.4x |
| Total assets | $280M | $211M | $174M | $157M | $91.5M |
| Total liabilities | $18.7M | $50.6M | $48.0M | $36.4M | $38.1M |
| Shareholders' equity | $261M | $161M | $126M | $121M | $53.4M |
| Net debt (β = net cash) | β | β | β | β | β |
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
In plain words: How much profit the business makes on the money put into it. A higher percentage means each dollar invested works harder.
Return on capital, equity and assets (annual)
KIRA Β· Pyxis Oncology, Inc. passes 2 of 8 financial health tests (Piotroski F-score).
Nine pass/fail tests of profitability, funding and efficiency. 8β9 is strong, 0β2 weak.
In plain words: Nine yes/no tests of financial health, one point each. A green tick is a pass: 7 to 9 points is solid, 0 to 3 is weak.
| Test | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|
| Net income is positive | β | β | β | β | β | β |
| Cash from operations is positive | β | β | β | β | β | β |
| Return on assets rose | β | β | β | β | β | β |
| Cash from operations exceeds net income | β | β | β | β | β | β |
| Debt fell relative to assets | β | β | β | β | β | β |
| Current ratio rose | β | β | β | β | β | β |
| Share count didn't rise | β | β | β | β | β | β |
| Gross margin rose | β | β | β | β | β | β |
| Revenue rose relative to assets | β | β | β | β | β | β |
| F-score | β / 3 | β / 6 | β / 6 | β / 6 | β / 6 | 2 / 8 |
| Accruals ratio | β27.0% | β28.0% | β12.8% | β1.6% | β11.9% | β13.0% |
| Altman Z'' | β15.00 | 18.02 | 0.95 | β2.07 | β3.10 | β16.86 |
Every number, year by year.
Amounts in USD. Hover a ratioβs name for its definition.
In plain words: Every number we have, year by year. Download it as a spreadsheet if you want to dig deeper.
| Fiscal year | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|
| Income statement | ||||||
| Revenue | β | β | β | β | $16.1M | $13.9M |
| Gross profit | β | β | β | β | $15.7M | $11.5M |
| Research and development | $9.0M | $51.1M | $86.1M | $49.6M | $58.7M | $73.7M |
| Operating income | β$12.9M | β$69.7M | β$123M | β$82.2M | β$89.5M | β$84.4M |
| Pretax income | β | β | β | β$73.8M | β$79.5M | β$78.2M |
| Income tax | β | β | β | β | β$2.2M | $1.4M |
| Net income | β$12.8M | β$76.0M | β$121M | β$73.8M | β$77.3M | β$79.6M |
| Diluted EPS | β$12.45 | β$8.95 | β$3.65 | β$1.85 | β$1.32 | β$1.28 |
| Diluted shares | 0.00B | 0.01B | 0.03B | 0.04B | 0.06B | 0.06B |
| Cash flow | ||||||
| Cash from operations | β$10.1M | β$35.3M | β$89.3M | β$70.7M | β$57.7M | β$63.5M |
| Capital expenditure | $1.5M | $0.5M | $6.4M | $6.7M | $0.2M | $0.0M |
| Free cash flow | β$11.6M | β$35.9M | β$95.7M | β$77.4M | β$57.9M | β$63.5M |
| Depreciation and amortization | $0.5M | $0.6M | $0.7M | $1.9M | $3.0M | $4.5M |
| Stock-based compensation | $0.0M | $6.4M | $15.8M | $16.9M | $12.9M | $11.8M |
| Balance sheet | ||||||
| Cash and short-term investments | $8.1M | $275M | $179M | $119M | $127M | $66.9M |
| Current assets | $8.1M | $279M | $187M | $125M | $132M | $72.1M |
| Current liabilities | $3.7M | $18.7M | $31.6M | $25.8M | $17.7M | $21.1M |
| Property and equipment, net | $1.1M | $1.0M | $11.2M | $11.9M | $9.9M | $8.0M |
| Intangible assets | β | β | β | $24.3M | $2.6M | $0.0M |
| Total assets | $10.2M | $280M | $211M | $174M | $157M | $91.5M |
| Total liabilities | $3.9M | $18.7M | $50.6M | $48.0M | $36.4M | $38.1M |
| Shareholders' equity | β$15.6M | $261M | $161M | $126M | $121M | $53.4M |
| Margins | ||||||
| Gross margin | β | β | β | β | 97.1% | 82.8% |
| Operating margin | β | β | β | β | β554.1% | β609.2% |
| EBITDA margin | β | β | β | β | β535.6% | β576.6% |
| Net margin | β | β | β | β | β478.9% | β574.5% |
| FCF margin | β | β | β | β | β358.7% | β458.3% |
| Returns | ||||||
| Return on capital employed | β199.5% | β26.7% | β68.7% | β55.6% | β64.1% | β119.9% |
| Return on equity | β | β61.9% | β57.2% | β51.5% | β62.8% | β91.4% |
| Return on assets | β126.4% | β52.4% | β49.1% | β38.3% | β46.7% | β64.0% |
| Return on tangible equity | β | β29.1% | β75.1% | β72.8% | β65.5% | β149.1% |
| Growth | ||||||
| Revenue growth | β | β | β | β | β | β14.2% |
| Share count change | β | 724.1% | 288.9% | 20.8% | 46.5% | 6.3% |
| Financial health | ||||||
| Current ratio | 2.2x | 14.9x | 5.9x | 4.8x | 7.5x | 3.4x |
| Quick ratio | 2.2x | 14.9x | 5.9x | 4.8x | 7.5x | 3.4x |
| Capital allocation | ||||||
| Capex / revenue | β | β | β | β | 1.5% | 0.1% |
| Stock comp / revenue | β | β | β | β | 80.2% | 85.2% |
| Quality scores | ||||||
| Piotroski F-score | β | β | β | β | β | 2.0 |
| Altman Z'' | β15.0 | 18.0 | 0.9 | β2.1 | β3.1 | β16.9 |
| Accruals ratio | β27.0% | β28.0% | β12.8% | β1.6% | β11.9% | β13.0% |
Source: SEC EDGAR XBRL filings (CIK 0001782223). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only β not investment advice. Check the original filings before relying on any figure.
